October 07, 2015.
Express Scripts (St. Louis, MO) announced yesterday that it will include two new cholesterol-lowering drugs on its National Preferred Formulary.
Sanofi's Praluent and Amgen's Repatha are the first PCSK9 inhibitors to be approved by FDA. Dr. Steve Miller, Senior Vice President and Chief Medical Officer of Express Scripts, commented: "Since these new medications were approved a few months ago, our pharmacy experts have worked with medical professionals and our plan sponsors to ensure these drugs are used specifically by patients who will benefit the most. We are pleased to include both drugs on our National Preferred Formulary, and to put innovative medicines within reach of patients who truly need them."
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.